Go to
JCI Insight
Citations to this article
Klaudia Kuranda, … , Philippe Veron, Federico Mingozzi
Published October 22, 2018
Citation Information: J Clin Invest. 2018;128(12):5267-5279. https://doi.org/10.1172/JCI122372.
Citation Information: J Clin Invest. 2018;128(12):5267-5279. https://doi.org/10.1172/JCI122372.
Abstract
Recombinant adeno-associated virus (AAV) vectors have been broadly adopted as a gene delivery tool in clinical trials, owing to their high efficiency of transduction of several host tissues and their low immunogenicity. However, a considerable proportion of the population is naturally exposed to the WT virus from which AAV vectors are derived, which leads to the acquisition of immunological memory that can directly determine the outcome of gene transfer. Here, we show that prior exposure to AAV drives distinct capsid immunity profiles in healthy subjects. In peripheral blood mononuclear cells (PBMCs) isolated from AAV-seropositive donors, recombinant AAV triggered TNF-α secretion in memory CD8+ T cells, B cell differentiation into antibody-secreting cells, and anti-capsid antibody production. Conversely, PBMCs isolated from AAV-seronegative individuals appeared to carry a population of NK cells reactive to AAV. Further, we demonstrated that the AAV capsid activates IL-1β and IL-6 cytokine secretion in monocyte-related dendritic cells (moDCs). IL-1β and IL-6 blockade inhibited the anti-capsid humoral response in vitro and in vivo. These results provide insights into immune responses to AAV in humans, define a possible role for moDCs and NK cells in capsid immunity, and open new avenues for the modulation of vector immunogenicity.
Authors
Klaudia Kuranda, Priscilla Jean-Alphonse, Christian Leborgne, Romain Hardet, Fanny Collaud, Solenne Marmier, Helena Costa Verdera, Giuseppe Ronzitti, Philippe Veron, Federico Mingozzi
Total citations by year
Citation information
Citations to this article (57)
| Title and authors | Publication | Year |
|---|---|---|
|
Challenges in Humoral Immune Response to Adeno-Associated Viruses Determination
Naumova DA, Krokunova T, Maksimov D, Mityaeva ON, Astakhova EA, Volchkov PY |
International Journal of Molecular Sciences | 2025 |
|
Impact of liver fibrosis on AAV-mediated gene transfer to mouse hepatocytes
Ferriero R, Bruno G, Padula A, Pisano S, Boffa I, Gargaro M, Imperatore T, Battipaglia M, Vivenzio S, Perna C, Nusco E, Ferrante L, Westhaus A, Knight M, Manni G, Campione S, Di Napoli E, Polishchuk E, Polishchuk R, Paciello O, Brunetti-Pierri N, Lisowski L, Fallarino F, Piccolo P |
Nature Communications | 2025 |
|
AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain
Costa-Verdera H, Meneghini V, Fitzpatrick Z, Abou Alezz M, Fabyanic E, Huang X, Dzhashiashvili Y, Ahiya A, Mangiameli E, Valeri E, Crivicich G, Piccolo S, Cuccovillo I, Caccia R, Chan YK, Bertin B, Ronzitti G, Engel EA, Merelli I, Mingozzi F, Gritti A, Kuranda K, Kajaste-Rudnitski A |
Nature Communications | 2025 |
|
Unveiling the sex bias: higher preexisting and neutralizing titers against AAV in females and implications for gene therapy.
Warrington S, Hoang TT, Seirup M, Abdelhamid L, Saha H, Bing S, Saleh S, Phue JN, Mazor R |
Gene therapy | 2025 |
|
Innate Immune Sensing of Adeno-Associated Virus Vectors.
Cao D, Byrne BJ, de Jong YP, Terhorst C, Duan D, Herzog RW, Kumar SRP |
Human Gene Therapy | 2024 |
|
Protein overexpression by adeno-associated virus-based gene therapy products in cardiomyocytes induces endoplasmic reticulum stress and myocardial degeneration in mice
Yasuno K, Watanabe R, Ishida R, Okado K, Kondo H, Iguchi T, Imaoka M, Tsuchiya Y |
Journal of Toxicologic Pathology | 2024 |
|
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva A, Kostyusheva A, Kachanov A, Brezgin S, Ponomareva N, Parodi A, Pokrovsky VS, Lukashev A, Chulanov V, Kostyushev D |
Cells | 2024 |
|
Polyfunctional T cells and unique cytokine clusters imprint the anti rAAV2/rAAV9 vector immune response
Holtkamp SJ, Lagoda FR, Lister A, Harish P, Kleymann U, Pesch T, Soon CF, Pirmohamed M, Naisbitt D, Trautwein M |
Frontiers in Immunology | 2024 |
|
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.
Arjomandnejad M, Dasgupta I, Flotte TR, Keeler AM |
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2023 |
|
Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar SR, Duan D, Herzog RW |
Human Gene Therapy | 2023 |
|
Prednisolone and rapamycin reduce the plasma cell gene signature and may improve AAV gene therapy in cynomolgus macaques.
Kistner A, Chichester JA, Wang L, Calcedo R, Greig JA, Cardwell LN, Wright MC, Couthouis J, Sethi S, McIntosh BE, McKeever K, Wadsworth S, Wilson JM, Kakkis E, Sullivan BA |
Gene Therapy | 2023 |
|
Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer
Tang L, Huang ZP, Mei H, Hu Y |
Military Medical Research | 2023 |
|
Circulating neurofilament light chain as a promising biomarker of AAV-induced dorsal root ganglia toxicity in nonclinical toxicology species
K Fader, I Pardo, R Kovi, C Somps, H Wang, V Vaidya, S Ramaiah, M Sirivelu |
Molecular Therapy — Methods & Clinical Development | 2022 |
|
Estimation of the in vivo neutralization potency of eCD4Ig and conditions for AAV-mediated production for SHIV long-term remission
A Goyal, M Gardner, B Mayer, K Jerome, M Farzan, J Schiffer, E Cardozo-Ojeda |
Science Advances | 2022 |
|
Basic Principles and Clinical Applications of CRISPR-Based Genome Editing
J Lim, H Kim |
Yonsei Medical Journal | 2022 |
|
Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression
L Wang, C Warzecha, A Kistner, J Chichester, P Bell, E Buza, Z He, M Pampena, J Couthouis, S Sethi, K McKeever, M Betts, E Kakkis, J Wilson, S Wadsworth, B Sullivan |
Molecular Therapy — Methods & Clinical Development | 2022 |
|
Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations
J Mendell, A Connolly, K Lehman, D Griffin, S Khan, S Dharia, L Quintana-Gallardo, L Rodino-Klapac |
Molecular Therapy — Methods & Clinical Development | 2022 |
|
Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients
Gross DA, Tedesco N, Leborgne C, Ronzitti G |
Frontiers in immunology | 2022 |
|
Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins Results in High Levels of Gene Editing in Primary Hepatocytes
Rathbone T, Ates I, Fernando L, Addlestone E, Lee CM, Richards VP, Cottle RN |
The CRISPR journal | 2022 |
|
Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy.
Gehrke M, Diedrichs-Möhring M, Bogedein J, Büning H, Michalakis S, Wildner G |
Cells | 2022 |
|
Cell-Based Determination of Neutralizing Antibodies Against Adeno-Associated Virus in Cardiac Gene Therapy.
Ravichandran AJ, Mazurek R, Ishikawa K |
Methods in molecular biology (Clifton, N.J.) | 2022 |
|
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper.
Yang TY, Braun M, Lembke W, McBlane F, Kamerud J, DeWall S, Tarcsa E, Fang X, Hofer L, Kavita U, Upreti VV, Gupta S, Loo L, Johnson AJ, Chandode RK, Stubenrauch KG, Vinzing M, Xia CQ, Jawa V |
2022 | |
|
Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood
Smith CJ, Ross N, Kamal A, Kim KY, Kropf E, Deschatelets P, Francois C, Quinn WJ III, Singh I, Majowicz A, Mingozzi F, Kuranda K |
Frontiers in immunology | 2022 |
|
The HLA class-II immunopeptidomes of AAV capsids proteins
Brito-Sierra CA, Lannan MB, Siegel RW, Malherbe LP |
Frontiers in immunology | 2022 |
|
Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia
PE Monahan, C Négrier, M Tarantino, LA Valentino, F Mingozzi |
Journal of Clinical Medicine | 2021 |
|
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
K Rapti, D Grimm |
Frontiers in immunology | 2021 |
|
T Cell-Mediated Immune Responses to AAV and AAV Vectors
HC Ertl |
Frontiers in immunology | 2021 |
|
Exploiting Single-Cell Tools in Gene and Cell Therapy
D Bode, AH Cull, JA Rubio-Lara, DG Kent |
Frontiers in immunology | 2021 |
|
The intersection of vector biology, gene therapy, and hemophilia
L Lisowski, JM Staber, JF Wright, LA Valentino |
Research and Practice in Thrombosis and Haemostasis | 2021 |
|
Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A
BR Long, P Veron, K Kuranda, R Hardet, N Mitchell, GM Hayes, WY Wong, K Lau, M Li, MB Hock, SJ Zoog, C Vettermann, F Mingozzi, B Schweighardt |
Molecular Therapy | 2021 |
|
Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses
YK Chan, SK Wang, CJ Chu, DA Copland, AJ Letizia, HC Verdera, JJ Chiang, M Sethi, MK Wang, WJ Neidermyer, Y Chan, ET Lim, AR Graveline, M Sanchez, RF Boyd, TS Vihtelic, RG Inciong, JM Slain, PJ Alphonse, Y Xue, LR Robinson-McCarthy, JM Tam, MH Jabbar, B Sahu, JF Adeniran, M Muhuri, PW Tai, J Xie, TB Krause, A Vernet, M Pezone, R Xiao, T Liu, W Wang, HJ Kaplan, G Gao, AD Dick, F Mingozzi, MA McCall, CL Cepko, GM Church |
Science Translational Medicine | 2021 |
|
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression
BA Konkle, CE Walsh, MA Escobar, NC Josephson, G Young, A von Drygalski, SW McPhee, RJ Samulski, I Bilic, M de la Rosa, BM Reipert, H Rottensteiner, F Scheiflinger, JC Chapin, B Ewenstein, PE Monahan |
Blood | 2021 |
|
Non‐coding RNAs in cardiomyocyte proliferation and cardiac regeneration: Dissecting their therapeutic values
X Dong, X Dong, F Gao, N Liu, T Liang, F Zhang, X Fu, L Pu, J Chen |
Journal of Cellular and Molecular Medicine | 2021 |
|
Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-γ ELISpot method
KS Patton, MT Harrison, BR Long, K Lau, J Holcomb, R Owen, T Kasprzyk, S Janetzki, SJ Zoog, C Vettermann |
Molecular Therapy — Methods & Clinical Development | 2021 |
|
Adeno-Associated Vector-Delivered CRISPR/SaCas9 System Reduces Feline Leukemia Virus Production In Vitro
AK Helfer-Hungerbuehler, J Shah, T Meili, E Boenzli, P Li, R Hofmann-Lehmann |
Viruses | 2021 |
|
Validation of an IFN-gamma ELISpot assay to measure cellular immune responses against viral antigens in non-human primates
F Yang, K Patton, T Kasprzyk, B Long, S Gupta, SJ Zoog, K Tracy, C Vettermann |
Gene Therapy | 2021 |
|
Apolipoprotein E, low-density lipoprotein receptor, and immune cells control blood-brain barrier penetration by AAV-PHP.eB in mice
BS Xie, X Wang, YH Pan, G Jiang, JF Feng, Y Lin |
Theranostics | 2021 |
|
Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme
Zachary C. Elmore, Daniel K. Oh, Katherine E. Simon, Marco M. Fanous, Aravind Asokan |
JCI Insight | 2020 |
|
Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans
G Gernoux, AM Gruntman, M Blackwood, M Zieger, TR Flotte, C Mueller |
Molecular Therapy | 2020 |
|
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
HC Verdera, K Kuranda, F Mingozzi |
Molecular Therapy | 2020 |
|
Immune Responses to Viral Gene Therapy Vectors
JL Shirley, YP de Jong, C Terhorst, RW Herzog |
Molecular Therapy | 2020 |
|
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
G Ronzitti, DA Gross, F Mingozzi |
Frontiers in immunology | 2020 |
|
Immune Response Mechanisms against AAV Vectors in Animal Models
AT Martino, DM Markusic |
Molecular Therapy — Methods & Clinical Development | 2020 |
|
The Immune Response to the fVIII Gene Therapy in Preclinical Models
SR Patel, TS Lundgren, HT Spencer, CB Doering |
Frontiers in immunology | 2020 |
|
Tetramer-Based Enrichment of Preexisting Anti-AAV8 CD8+ T Cells in Human Donors Allows the Detection of a TEMRA Subpopulation
C Vandamme, R Xicluna, L Hesnard, M Devaux, N Jaulin, M Guilbaud, JL Duff, C Couzinié, P Moullier, X Saulquin, O Adjali |
Frontiers in immunology | 2020 |
|
Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells
JL Shirley, GD Keeler, A Sherman, I Zolotukhin, DM Markusic, BE Hoffman, LM Morel, MA Wallet, C Terhorst, RW Herzog |
Molecular Therapy | 2020 |
|
Characterization of hepatic macrophages and evaluation of inflammatory response in heme oxygenase-1 deficient mice exposed to scAAV9 vectors
M Tomczyk, I Kraszewska, R Mąka, A Waligórska, J Dulak, A Jaźwa-Kusior, AS Lewin |
PloS one | 2020 |
|
Recruiting the innate immune system with GM-CSF to fight viral diseases, including West Nile Virus encephalitis and COVID-19
H Potter, TD Boyd, P Clarke, VS Pelak, KL Tyler |
F1000Research | 2020 |
|
Delivery Approaches for Therapeutic Genome Editing and Challenges
I Ates, T Rathbone, C Stuart, PH Bridges, RN Cottle |
Genes & development | 2020 |
|
Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates
BJ Samelson-Jones, JD Finn, P Favaro, JF Wright, VR Arruda |
Molecular Therapy — Methods & Clinical Development | 2020 |
|
TLR9-activating CpG-B ODN but not TLR7 Agonists Trigger Antibody Formation to Factor IX in Muscle Gene Transfer
JS Butterfield, M Biswas, JL Shirley, SR Kumar, A Sherman, C Terhorst, C Ling, R Herzog |
Human Gene Therapy Methods | 2019 |
|
Progress and challenges of gene therapy for Pompe disease
G Ronzitti, F Collaud, P Laforet, F Mingozzi |
Annals of translational medicine | 2019 |
|
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
NF Nidetz, MC McGee, LV Tse, C Li, L Cong, Y Li, W Huang |
Pharmacology & Therapeutics | 2019 |
|
Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats
P Li, E Boenzli, R Hofmann-Lehmann, AK Helfer-Hungerbuehler, JA Chiorini |
PloS one | 2019 |
|
Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors
A Kruzik, D Fetahagic, B Hartlieb, S Dorn, H Koppensteiner, FM Horling, F Scheiflinger, BM Reipert, M de la Rosa |
Molecular Therapy — Methods & Clinical Development | 2019 |
|
Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer
S Pipe, FW Leebeek, V Ferreira, EK Sawyer, J Pasi |
Molecular Therapy — Methods & Clinical Development | 2019 |
|
AAV Immunogenicity: New Answers Create New Questions
JL Shirley, RW Herzog |
Molecular Therapy | 2018 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)